Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

82P - Results from FRONT study: A multicenter, randomized, open-label clinical trial of fruquintinib as maintenance therapy after 1L treatment in metastatic colorectal cancer (mCRC)

Date

07 Dec 2024

Session

Poster Display session

Presenters

Xiaojing Xu

Citation

Annals of Oncology (2024) 35 (suppl_4): S1432-S1449. 10.1016/annonc/annonc1687

Authors

X. Xu1, Y. Yu1, Q. Liu1, Y. Wang1, Y. Cui1, W. Li1, Q. Li1, Y. Feng1, L. Liang1, S. Yu1, Z. Lv2, T. Liu1

Author affiliations

  • 1 Department Of Oncology, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN
  • 2 Department Of Biostatistics, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN

Resources

This content is available to ESMO members and event participants.

Abstract 82P

Background

Maintenance treatment and treatment discontinuation are options to mCRC patients who response to first-line treatment. We conducted this study to evaluate the efficacy and safety of fruquintinib as maintenance therapy following first-line treatment for mCRC.

Methods

FRONT study is an ongoing, multicenter, open-label, randomized clinical trial. Patients (pts) with unresectable right-sided mCRC or RAS-mutant left-sided mCRC, who hadn’t had progressed disease after first-line standard treatment (chemotherapy with or without bevacizumab) for four to six months, were eligible. According to the protocol, 110 patients would be randomly allocated to fruquintinib (FR) group (4mg orally per day in 21-day-on/7-day-off cycles) or observation (OB) group at a 2:1 ratio via interactive web response system. The primary endpoint was progression-free survival (PFS).

Results

Up to June 20, 2024, 36 and 19 patients had been enrolled in FR group and OB group, of whom the median age was 59.5 (44 to 73) vs. 66 (36 to 81), including 25 (69%) vs. 13 (68%) males, respectively. With a median follow-up of 19.12 months, 35 and 19 pts in two groups received at least one response evaluation after baseline. The median PFS were 3.91 (95% CI: 3.09-8.15) months and 2.94 (95% CI: 1.97-4.63) months (HR=0.48, 95% CI: 0.24 to 0.95; univariate Cox proportional hazard p=0.0341). The 3-month PFS rate was 70.94 (95% CI: 53.75-88.14) % vs. 44.44 (95% CI: 21.49-67.40) %, and the 6-month PFS rate was 43.35 (95% CI: 22.96-63.74) % vs. 20.00 (0.61-39.38) %.The DCR was 85.71% (30/35) vs. 52.63% (10/19) (OR=5.40, 95% CI: 1.46-19.95; Fisher exact test p=0.0203). The common AEs in FR group were hypertension, hand-foot syndrome, fatigue, rash, oral mucositis, and proteinuria, while AEs of grades≥3 were hand-foot syndrome, hypertension, oral mucositis, and proteinuria.

Conclusions

Compared to treatment discontinuation, fruquintinib demonstrated better outcomes as a maintenance therapy after first-line treatment with acceptable toxicity in mCRC.

Clinical trial identification

NCT04296019.

Editorial acknowledgement

The authors thank all the patients involved in this study. We also thank Chao Zhao and Zheng Wang from HUTCHMED for the assistance in data analysis and writing.

Legal entity responsible for the study

The authors.

Funding

Chinese Society of Clinical Oncology Eli Lilly and Company Pharmaceutical/Biotech Company.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.